ACM
SPRY icon

Aster Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Aster Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.39K Buy
349
+196
+128% +$1.88K ﹤0.01% 691
2025
Q4 		$1.78K Buy
+153
New +$1.49K ﹤0.01% 963
2025
Q3 		– Sell
-268
Closed -$4.68K – 1337
2025
Q2 		$4.68K Sell
268
-2,823
-91% -$40.7K ﹤0.01% 873
2025
Q1 		$32.4K Buy
3,091
+2,483
+408% +$29.9K 0.01% 909
2024
Q4 		$6.41K Buy
+608
New +$8.52K ﹤0.01% 829

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aster Capital Management's SPRY Position: Q1 2026 in Review

Aster Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 128% in Q1 2026, buying an estimated $1.88K and bringing the position to 349 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #691.

Aster Capital Management first reported a position in SPRY in Q4 2024 and has held it in 5 quarters since. The position peaked at $32.4K in Q1 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Aster Capital Management held 349 shares of ARS Pharmaceuticals worth $4.39K as of Q1 2026.
  • Aster Capital Management bought 196 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.88K.
  • ARS Pharmaceuticals made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #691 holding.
  • Aster Capital Management first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Aster Capital Management's ARS Pharmaceuticals position peaked at $32.4K in Q1 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.